GB2477227A — A electrical isolation member for an electronic auto-injector
Assigned to Intelliject Inc · Expires 2011-07-27 · 15y expired
What this patent protects
An auto-injector 4002 is first enabled by removing the needle guard 4810 and the safety lock 4710. As illustrated by arrow AA in FIG. 57, the needle guard 4810 is removed by moving it distally. The sheath retainer 4840 includes an actuator 4864 that is received by an opening 4862…
USPTO Abstract
An auto-injector 4002 is first enabled by removing the needle guard 4810 and the safety lock 4710. As illustrated by arrow AA in FIG. 57, the needle guard 4810 is removed by moving it distally. The sheath retainer 4840 includes an actuator 4864 that is received by an opening 4862 in the isolation tab 4860. Accordingly, when the sheath retainer 4840 is moved distally away from the base 4520, the isolation tab 4860 is removed from the area between the first electrical contact portion 4936 of the printed circuit board 4922 and the first surface 4964 of one of the batteries 4962. In this manner, the batteries 4962 can be operatively coupled to the electronic circuit system 4920 when the needle guard 4810 is removed, thereby actuating the electronic circuit system 4920.
Drugs covered by this patent
- naloxone-hydrochloride (Naloxone Hydrochloride) · Pfizer Inc.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.